GI Research Institute

Vancouver, British Columbia V6Z2K5

1 studies enrolling now · 20 studies all time

What they study most

Alpha1-Antitrypsin Deficiency, Chronic Constipation, Chronic Hepatitis B, Chronic Hepatitis C Infection, Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Hepatitis B, Chronic, Hepatitis C Virus Infection, Irritable Bowel Syndrome With Constipation, Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease, Pancreatic Cancer

Studies at this site

• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein — Recruiting now
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection — Stopped early
• A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients — Stopped early
• Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) — Status unconfirmed
• Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis — Completed
• Longitudinal Pancreatic Cancer Study — Completed
• A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV) — Completed
• Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation — Completed
• A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease — Stopped early
• A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease — Completed
• An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis — Completed
• Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay — Completed
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling
• A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed